UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               AMENDMENT NO. 20 TO
                                  SCHEDULE 13D

                    Under the Securities Exchange Act of 1934



                                  MetLife, Inc.
                                (Name of Issuer)

                     Common Stock, par value $.01 per share
                         (Title of Class of Securities)

                                    59156R108
                                 (CUSIP Number)

                             James L. Lipscomb, Esq.
                  Executive Vice-President and General Counsel
                                  MetLife, Inc.
                                 200 Park Avenue
                           New York, NY 10166-0188
                                 (212) 578-2211
       (Name, Address and Telephone Number of Person Authorized to Receive
                           Notices and Communications)


                                 March 7, 2005
             (Date of Event which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report
the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g),
check the following box [ ].

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purposes of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).


                               Page 1 of 10 Pages

                                  SCHEDULE 13D
CUSIP No. 59156R108                                           Page 2 of 10 Pages
--------------------------------------------------------------------------------

(1)   Names of Reporting Persons          Board of Directors of MetLife, Inc.,
                                          as an entity
      I.R.S. Identification
      Nos. of Above Persons               Not applicable

--------------------------------------------------------------------------------

(2)   Check the Appropriate Box                                       (a) [    ]
      if a Member of a Group                                          (b) [    ]

--------------------------------------------------------------------------------

(3)   SEC Use Only

--------------------------------------------------------------------------------

(4)   Source of Funds                                 Not Applicable. See Item 4

--------------------------------------------------------------------------------

(5)   Check if Disclosure of Legal 
      Proceedings is Required Pursuant
      to Items 2(d) or 2(e)                                               [    ]
--------------------------------------------------------------------------------

(6)   Citizenship or Place of
      Organization

                                                                        U.S.A.

--------------------------------------------------------------------------------

Number of Shares         (7) Sole Voting Power                               0
Beneficially Owned
by Each Reporting       --------------------------------------------------------
Person With       
                         (8) Shared Voting Power                   317,387,457*

                        --------------------------------------------------------

                         (9) Sole Dispositive Power                          0

                        --------------------------------------------------------

                         (10) Shared Dispositive Power                       0

--------------------------------------------------------------------------------

(11)  Aggregate Amount Beneficially
      Owned by Each Reporting Person                               317,387,457

--------------------------------------------------------------------------------

(12)  Check if the Aggregate Amount
      in Row (11) Excludes Certain Shares                                 [    ]

--------------------------------------------------------------------------------

(13)  Percent of Class Represented
      by Amount in Row 11                                                 43.2%

--------------------------------------------------------------------------------

(14)  Type of Reporting Person

                                                                             OO

--------------------------------------------------------------------------------

* Unless otherwise indicated, all information relating to beneficial ownership
  of the Shares by the Reporting Persons is as of February 28, 2005.

                                  SCHEDULE 13D
CUSIP No. 59156R108                                           Page 3 of 10 Pages

Items 4 and 5 are amended as set forth below:

ITEM 4.     PURPOSE OF TRANSACTION.

            The Board of Directors is reporting beneficial ownership of
317,387,457 shares of Common Stock (the "Shares") held by the MetLife
Policyholder Trust (the "Trust") under the Plan of Reorganization, dated
September 28, 1999, as amended (the "Plan"), of Metropolitan Life Insurance
Company ("MetLife").

            On April 7, 2000, 494,466,664 Shares were issued to the Trust
pursuant to Section 5.2(d) of the Plan, a copy of which is filed as an exhibit
to this statement. No consideration has been separately provided therefor by any
member of the Board of Directors, except for Shares allocated to such member
pursuant to the Plan. Since April 7, 2000, transactions by Beneficiaries under
the Purchase and Sale Program provided for by the Trust Agreement (as defined
below) have resulted in a decrease in the number of Shares held by the Trust
from 494,466,664 to 317,387,457 (as adjusted to reflect refinements in the
calculation of the number of Shares issued to the Trust under the Plan).

            Under the Plan and the MetLife Policyholder Trust Agreement, dated
as of November 3, 1999 (as amended, the "Trust Agreement"), by and among
MetLife, the Issuer, Wilmington Trust Company (the "Trustee") and ChaseMellon
Shareholder Services, L.L.C., as custodian (now known as Mellon Investor
Services LLC, the "Custodian"), a copy of which is attached as an exhibit to
this statement, certain eligible policyholders of MetLife ("Trust Eligible
Policyholders") have been allocated a number of interests in the Trust ("Trust
Interests") equal to the number of shares of Common Stock allocated to the Trust
Eligible Policyholders in accordance with the Plan. The assets of the Trust
principally are the Shares issued to the Trust for the benefit of the Trust
Eligible Policyholders and permitted transferees (collectively, the
"Beneficiaries"). The Shares are held in the name of the Trustee, on behalf of
the Trust, which has legal title over the Shares. The Beneficiaries do not have
legal title to any part of the assets of the Trust. The Trust Interests
represent undivided fractional interests in the Shares and other assets of the
Trust beneficially owned by a Trust Beneficiary through the Custodian.

            The Trust Agreement provides the Trustee with directions as to the
manner in which to vote, assent or consent the Shares at all times during the
term of the Trust. On all matters brought for a vote before the stockholders of
the Issuer, with the exception of a Beneficiary Consent Matter (as defined
below), the Trustee will vote in accordance with the

                                  SCHEDULE 13D
CUSIP No. 59156R108                                           Page 4 of 10 Pages

recommendation given by the Board of Directors of the Issuer to its stockholders
or, if no such recommendation is given, as directed by the Board. On all
Beneficiary Consent Matters, the Trustee will vote all of the Shares in favor
of, in opposition to or abstain from the matter in the same ratio as the Trust
Interests of the Beneficiaries that returned voting instructions to the Trustee
indicated preferences for voting in favor of, in opposition to or abstaining
from such matter. The Trust Agreement also contains provisions allowing
Beneficiaries to instruct the Custodian to withdraw their allocated Trust Shares
to participate in any tender or exchange offer for the Common Stock and to make
any cash or share election, or perfect any dissenter's rights, in connection
with a merger of the Issuer.

            A "Beneficiary Consent Matter" is:

      (i)   a contested election of directors or, subject to certain conditions,
            the removal of a director,

      (ii)  a merger or consolidation, a sale, lease or exchange of all or
            substantially all of the assets or a recapitalization or dissolution
            of the Issuer, if it requires a vote of stockholders under
            applicable Delaware law,

      (iii) any transaction that would result in an exchange or conversion of
            the Shares for cash, securities or other property,

      (iv)  issuances of Common Stock prior to the first anniversary of the
            effective date of the Plan (the "Effective Date") at a price
            materially below the prevailing market price, if a vote is required
            to approve the issuance under Delaware law, other than issuances in
            an underwritten public offering or pursuant to an employee benefit
            plan,

      (v)   before the first anniversary of the Effective Date, any matter that
            requires approval by a vote of more than a majority of the
            outstanding stock of the Issuer entitled to vote thereon under
            Delaware law or the certificate of incorporation or the by-laws of
            the Issuer, and any amendment to the certificate of incorporation or
            by-laws of the Issuer that is submitted to a vote of stockholders
            for approval, and

      (vi)  proposals submitted to stockholders requiring the Board of Directors
            to amend the Issuer's Stockholder Rights Plan, or redeem rights
            under that plan, other than a proposal with respect to which the
            Issuer has received advice of nationally-recognized legal counsel to
            the effect that the proposal is not a proper subject for stockholder
            action under Delaware law.

            The Trust Agreement contains provisions enabling the Beneficiaries
to withdraw the Shares allocated to them under the Plan and the Trust Agreement
for resale or otherwise and to receive dividends on such Shares.

                                  SCHEDULE 13D
CUSIP No. 59156R108                                           Page 5 of 10 Pages

ITEM 5.     INTEREST IN SECURITIES OF THE ISSUER.

      (a)   As an entity, the Board of Directors of the Issuer beneficially owns
            317,387,457 shares or 43.2% of the Issuer's outstanding Common
            Stock. The Board of Directors of the Issuer is deemed to
            beneficially own the shares of Common Stock held by the Trust
            because the Board will direct the voting of these shares on certain
            matters submitted to a vote of stockholders. See Item 4.

      (b)   As an entity, the Board of Directors of the Issuer has shared voting
            power with respect to 317,387,457 shares of Common Stock.

      (c)   Except as described in Item 4, there were no transactions in the
            class of securities reported on that were effected by the Reporting
            Persons since October 31, 2004 other than transactions by
            Beneficiaries under the Purchase and Sale Program provided for by
            the Trust Agreement, resulting in a decrease in the number of shares
            of Common Stock held by the Trust from 324,080,296 to 317,387,457.

      (d)   The Beneficiaries of the Trust have the right to receive or the
            power to direct the receipt of dividends from, or the proceeds from
            the sale of, the Shares allocated to them under the Plan and the
            Trust Agreement. See Item 4.

                                  SCHEDULE 13D
CUSIP No. 59156R108                                           Page 6 of 10 Pages

            SIGNATURES.

            After reasonable inquiry and to the best of my knowledge and belief,
we certify that the information set forth in this statement is true, complete
and correct.

Dated:  March 7, 2005



            *                 
------------------------------
Curtis H. Barnette

            *                 
------------------------------
Robert H. Benmosche

            *                 
------------------------------
Burton A. Dole, Jr.


            *                 
------------------------------
Cheryl W. Grise


            *                 
------------------------------
James R. Houghton

            *                 
------------------------------
Harry P. Kamen

            *                 
------------------------------
Helene L. Kaplan

            *                 
------------------------------
John M. Keane

            *                 
------------------------------
James M. Kilts

            *                 
------------------------------
Charles M. Leighton

            *                 
------------------------------
Sylvia M. Mathews

                                  SCHEDULE 13D
CUSIP No. 59156R108                                           Page 7 of 10 Pages

            *                 
------------------------------
Hugh B. Price

            *                 
------------------------------
Kenton J. Sicchitano

            *                 
------------------------------
William C. Steere, Jr.


      * By  /s/ Gwenn L. Carr
            -------------------------------
            Gwenn L. Carr
            Attorney-in-fact